PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): restructuring charge — PacBio reports preliminary Q1 revenue $36.9M, down 5% YoY; cuts annual opex run rate by $45-50M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2025-Q1 EPS reported -$1.44 revenue$37,153,000

Preliminary Q1 2025 revenue $36.9M vs $38.8M YoY; instrument revenue fell to $10.8M from $19.0M.
Record consumable revenue of $20.1M (up from $16.0M); shipped 28 Vega systems in Q1 (vs 0 prior).
Announces plan to reduce annualized non-GAAP opex run rate by $45-50M; expects ~$5M severance costs in 2025.
Reiterates FY2025 revenue guidance $155-170M and non-GAAP gross margin 35-40%; targets positive cash flow by end of 2027.
Cash and investments $343.1M at Q1 end; expects higher ending balance after cost cuts.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.7

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. announced a restructuring with charges of approximately $5 million in 2025.

Type: restructuring
Charge: approximately $5 million in 2025

Exact text from the filing

In connection with the plan, the Company estimates that it will incur approximately $5 million in 2025, consisting primarily of employee severance and benefit costs, which will be future cash expenditures.

View on SEC.gov

Browse all restructurings & charges →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001299130-25-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.